Search > IgA Nephropathy
32 Participants NeededMy employer runs this trial

Zigakibart for IgA Nephropathy

(SHIFT Trial)

Recruiting at 7 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Novartis Pharmaceuticals
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.

Who Is on the Research Team?

NP

Novartis Pharmaceuticals

Principal Investigator

Novartis Pharmaceuticals

Are You a Good Fit for This Trial?

Inclusion Criteria

My kidney disease was confirmed by a biopsy within the last 5 years.
My kidney function is good, with an eGFR of 45 or higher.
I have ongoing issues with high protein levels in my urine.
See 2 more

What Are the Treatments Tested in This Trial?

Interventions

  • zigakibart

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: zigakibartExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Novartis Pharmaceuticals

Lead Sponsor

Trials
2,963
Recruited
4,275,000+
Founded
1996
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Gleevec, Cosentyx, Entresto, Kisqali
Dr. Vas Narasimhan profile image

Dr. Vas Narasimhan

Novartis Pharmaceuticals

Chief Executive Officer since 2018

MD from Harvard Medical School

Dr. Shreeram Aradhye profile image

Dr. Shreeram Aradhye

Novartis Pharmaceuticals

Chief Medical Officer since 2021

MD

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.